Mast cell chymase promotes hypertrophic scar fibroblast proliferation and collagen synthesis by activating TGF-β1/Smads signaling pathway

Abstract

The present study assessed the existence of mast cell chymase in hypertrophic scars and determined whether chymase promotes fibrosis via the transforming growth factor (TGF)-β1/Smads signaling pathway. Five patients with hypertrophic scars and another five patients subjected to repair and reconstruction of other tissue defects were included in the present study. To detect the existence of mast cells and mast cell chymase in hypertrophic scars, immunohistochemistry was employed. To test the effect of chymase on TGF-β1, angiotensin, and type I and III collagen mRNA expression in isolated hypertrophic scar fibroblasts in vitro, reverse-transcription quantitative PCR was performed. To investigate how chymase affects TGF-β1, phosphorylated (P)-Smad2/3 as well as Smad4 and Smad7 protein expression, western blot analysis was used. Mast cell chymase was identified to promote the mRNA expression of TGF-β1, angiotensin, and type I and III collagen in hypertrophic scar fibroblasts in a time- and dose-dependent manner. Furthermore, treatment with 60 ng/ml mast cell chymase for 12 h led to the upregulation of TGF-β1, P-Smad2/3, Smad4 and Smad7 in hypertrophic scar fibroblasts. The present study demonstrated that mast cells and chymase are present in hypertrophic scars, and chymase promotes hypertrophic scar fibroblast proliferation and collagen synthesis by activating the TGF-β1/Smads signaling pathway.

Introduction

Hypertrophic scars are a common type of post-traumatic tissue repair abnormality (1). Hypertrophic scars formed during wound healing are mainly characterized by the overexpression of multiple fibrogenic factors, as well as excessive synthesis and reduced degradation of extracellular matrix, such as collagen (2). However, their pathogenesis has remained to be fully elucidated.

Chymase secreted by mast cells is a type of serine protease and its release activates transforming growth factor (TGF)-β1 via paracellular secretion stimulation and fibrinolysin (3–5). A previous study demonstrated that chymase has a potential role in tissue fibrosis (6). In addition, chymase secreted by mast cells was found to promote the release of TGF-β1 in the extracellular matrix of human epithelial and endothelial cells (7). It was also reported that chymase facilitates cell proliferation via the TGF-β1 signaling pathway (8).

The TGF-β1/Smads signaling pathway has been demonstrated to have important roles in the formation of hypertrophic scars (9). TGF-β1 stimulates the proliferation of fibroblasts and the production of collagen, and inhibits matrix degradation, finally leading to the formation of hypertrophic scars (10). Inhibition of the TGF-β1/Smads signaling pathway was reported to suppress the formation of hypertrophic scars (11). TGF-β is a cytokine that activates the intracellular Smad signaling pathway and has a key role in promoting wound healing and tissue remodeling after repair (10). Smad proteins are among the most important intracellular signal transduction proteins downstream of the TGF-β superfamily (12–14). Mast cells exist in hypertrophic scars and have a role in their formation (15). However, it has remained elusive whether chymase secreted by mast cells activates the Smad signaling pathway via TGF-β1 in hypertrophic scars. In the present study, the role of mast cell chymase in the in hypertrophic scar fibroblast formation via the TGF-β1/Smads signaling pathway was investigated.

Materials and methods

Subjects

A total of 5 patients with hypertrophic scars and an additional 5 patients subjected to repair and reconstruction of other tissue defects at the Department of Burns and Plastic Surgery, the First Affiliated Hospital of Xinjiang Medical University between May 2014 and May 2015 were included in the present study. The subjects were otherwise healthy and none of them had received any anti-scar treatment within two years or had any systemic disease. A piece of tissue was cut from each hypertrophic scar for histochemical examination in order to further confirm the validity of the clinical diagnosis (Table I). All procedures were approved by the Ethics Committee of Xinjiang Medical University (Urumqi, China). Written informed consent was obtained from all subjects or their families.

Table I.

Sources of hypertrophic scars.

Group	Age (years)	Gender	Scar location	Family history	Course of disease
HSFs	24	Female	Chest	−	9 months
	31	Female	Neck	+	25 months
	26	Female	Upper arm	−	10 months
	29	Female	Chest	+	8 months
	21	Female	Ear	−	14 months
NFs	20	Male	Abdomen	−	1 year
	25	Female	Abdomen	−	2 years
	27	Female	Shank	−	6 months
	41	Female	Forearm	−	3 years
	23	Female	Forearm	−	8 months

Family history refers to a family history of pathological scars, including keloid and hypertrophic scars. HSFs, hypertrophic scar fibroblasts; NFs, normal fibroblasts.

Cells

Hypertrophic scar samples were washed with PBS containing ampicillin and streptomycin (HyClone; GE Healthcare, Little Chalfont, UK), and epithelial and subcutaneous adipose tissues were removed. The samples were cut into 1-mm³ pieces and cultured in low-glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (both from HyClone; GE Healthcare) at 37°C under 5% CO₂. The medium was refreshed twice a week and finally, hypertrophic scar fibroblasts were obtained. When the fibroblasts reached 70–80% confluence, 0.25% trypsin (HyClone; GE Healthcare, Logan, UT, USA) was used to digest the cells, which were then collected split for further culture. The medium was refreshed every two days, and the growth speed and morphology of the fibroblasts were observed under an inverted phase contrast microscope. The cells at passage 3–6 were used for the experiments.

Immunohistochemical staining

Sample tissues from each group (hypertrophic scar and normal skin) were enclosed with pathological filter paper, fixed immediately with 10% buffered formalin at room temperature overnight, processed through graded alcohols and xylene, embedded in paraffin, and sectioned at 5-µm thickness (3 replicates for each specimen). Mast cells and mast cell chymase were immunohistochemically stained using polyclonal rabbit anti-human CD117 (1:500; cat no. LS-C20514; c-Kit; LifeSpan BioSciences, Inc., Seattle, WA, USA) antibody and polyclonal mouse anti-chymase antibody (1:500; cat no. kl086Bo01; Gene Company Ltd., Shanghai, China), respectively, and incubated at 4°C overnight. Samples were subsequently incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:1,000; cat no. GK500705; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) at 37°C for 30 min. Positive expression of CD117 and chymase was indicated by brown staining of cell membrane and cytoplasm. As a negative control, PBS was used instead of primary antibodies.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Hypertrophic scar fibroblasts were treated with different concentrations (0, 15, 30, 60 and 120 ng/ml) of chymase (cat no. C8118; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 6, 12 and 24 h prior to analysis. Total RNA was extracted from the cells at the first passage using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Complementary DNA was obtained by RT using the TIANScript RT kit (Tiangen, Beijing, China) at 37°C for 15 min, followed by an enzyme inactivation reaction at 98°C for 5 min. The primers were as follows: TGF-β1 (158 bp), 5′-ACACCAACTATTGCTTCAG-3′ (forward) and 5′-TGTCCAGGCTCCAAATG-3′ (reverse); collagen type I, α1 (COL1A1; 147 bp), 5′-CCCGGGTTTCAGAGAGACAACTTC-3′ (forward) and 5′-TCCACATGCTTTATTCCAGCAATC-3′ (reverse); COL3A1 (244 bp), 5′-CTTCTCTCCAGCCGAGCTTC-3′ (forward) and 5′-GTAGTCTCACAGCCTTGCGT-3′ (reverse); angiotensin (197 bp), 5′-CAAGGTGGAGGGTCTCAC-3′ (forward) and 5′-CTGATGCGGTCATTGCTC-3′ (reverse); β-actin (187 bp), 5′-TGGCACCCACAATGAA-3′ (forward) and 5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′ (reverse). PCR was performed on a thermo cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using a QuantiFast SYBR-Green PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's manual. The PCR reaction protocol was as follows: Initial denaturation at 95°C for 5 min, followed by 39 cycles of 95°C for 10 sec and 60°C for 30 sec. Quantitative measurements were performed using the 2^−∆∆Cq method (16), and β-actin was used as an internal reference. Each sample was measured in triplicate.

Western blot analysis

After washing with ice-cold PBS twice, the 4th passage of the cells were lysed using pre-cooled radioimmunoprecipitation assay lysis buffer and phenylmethanesulfonyl fluoride (both from Thermo Fisher Scientific, Inc.) for 50 min on ice. The mixture was then centrifuged at 12,000 × g and 4°C for 5 min. The supernatant was used to determine the protein concentration by using a bicinchoninic acid protein concentration determination kit (BioTeke Corp., Beijing, China). After denaturation, the samples were subjected to 12% SDS-PAGE. The resolved proteins were transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA) on ice and blocked with 5% skimmed milk at room temperature for 1 h. The membranes were then incubated with TGF-β1 antibody (1:300 dilution; cat no. sc-146), Smad7 (1:300 dilution; cat no. sc-11392), Smad4 (1:300 dilution; cat no. sc-7966), GAPDH (1:300 dilution; cat no. sc-25778) (all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or p-Smad2/3 (1:1,000 dilution; cat no. 8828s; Cell Signaling Technology, Inc., Beverly, MA, USA) at 4°C overnight. After washing with Tris-buffered saline with Tween-20 for 2 h, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1:1,000 dilution; cat no. 77054s; Cell Signaling Technology, Inc.) at room temperature for 2 h. The membrane was then developed using an enhanced chemiluminescence detection kit (Sigma-Aldrich; Merck KGaA) for imaging on X-ray film (ChemiDoc MP; Bio-Rad Laboratories, Inc.). Band intensity was acquired and analyzed using Quantity One software (version 4.6.2; Bio-Rad Laboratories, Inc.).

Statistical analysis

The results were analyzed using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). Values are expressed as the mean ± standard deviation. Differences between groups were analyzed using general linear single-factor analysis of variance and two-tailed t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Mast cells and active expression of chymase are present in hypertrophic scar tissues

To detect the existence of mast cells and mast cell chymase in hypertrophic scars, immunohistochemistry was employed. The results demonstrated that in hypertrophic scar tissues, the number of mast cells, identified by brown staining of membranes, was greater than that in normal skin tissues (Fig. 1A and B). In addition, chymase expression in hypertrophic scar tissues was higher than that in normal skin, as indicated by the higher number of brown particles in the cell cytoplasm (Fig. 1C and D). These results suggested that mast cells and active expression of chymase were present in hypertrophic scar tissues.

Figure 1.

Immunohistochemical staining of mast cells of (A) normal skin and (B) hypertrophic scar tissue with anti-CD117 antibodies. Staining of (C) normal skin and (D) hypertrophic scar tissue for mast cell chymase (magnification, ×400; scale bar, 50 µm).

Mast cell chymase promotes the mRNA expression of TGF-β1, angiotensin and type I and III collagen in hypertrophic scar fibroblasts in a time- and dose-dependent manner

To assess the effect of chymase on TGF-β1, angiotensin, and type I and III collagen mRNA expression in hypertrophic scar fibroblasts, RT-qPCR was performed. The results demonstrated that treatment with various concentrations of chymase for 6, 12 and 24 h increased TGF-β1 mRNA expression compared with that in the control group, particularly treatment with 120 ng/ml chymase for 12 h (Fig. 2A). Similar results were obtained for angiotensin mRNA expression, particularly after treatment with 60 and 120 ng/ml chymase for 12 h, and 15 and 30 ng/ml chymase for 24 h (Fig. 2B). Particularly after treatment with 60 and 120 ng/ml chymase for 12 h, type I collagen mRNA expression was enhanced compared with that in the control cells (Fig. 2C). Type III collagen mRNA expression was increased after incubation with various chymase concentrations for 12 or 24 h (Fig. 2D). These results indicated that mast cell chymase promotes the mRNA expression of TGF-β1, angiotensin, and type I and III collagen in hypertrophic scar fibroblasts in a time- and dose-dependent manner.

Figure 2.

Effect of chymase on the mRNA expression of TGF-β1, angiotensin, and type I and III collagen in hypertrophic scar fibroblasts. Reverse-transcription quantitative polymerase chain reaction analysis was used to measure the mRNA expression after treatment with different concentrations of chymase (0, 15, 30, 60 and 120 ng/ml) for 6, 12 or 24 h. mRNA expression of (A) TGF-β1, (B) angiotensin, (C) type I collagen and (D) type III collagen relative to β-actin. All experiments were performed in triplicate. Values are expressed as the mean ± standard deviation. *P<0.05 compared with control (0 ng/ml chymase). TGF, transforming growth factor.

Treatment with 60 ng/ml mast cell chymase for 12 h upregulates TGF-β1, P-Smad2/3, Smad4 and Smad7 protein expression in hypertrophic scar fibroblasts

To investigate how chymase affects TGF-β1, Smad4 and Smad7 protein expression as well as P-Smad2/3 levels, western blot analysis was performed. The results revealed that treatment with 60 or 120 ng/ml chymase for 12 h significantly enhanced TGF-β1 protein expression compared with that in the control cells (0 ng/ml chymase) (P<0.05; Fig. 3A). In addition, treatment with 60 ng/ml chymase for 12 h significantly increased P-Smad2/3 levels compared with those in the control cells (P<0.05; Fig. 3B). Similarly, treatment with 60 ng/ml chymase for 12 h significantly increased Smad4 protein expression compared with that in the control (P<0.05; Fig. 3C). Furthermore, treatment with 60 or 120 ng/ml chymase for 6 or 12 h significantly elevated Smad 4 and Smad7 protein expression compared with that in the control (P<0.05; Fig. 3D and E). The results suggested that treatment with 60 ng/ml mast cell chymase for 12 h led to an upregulation of TGF-β1, P-Smad2/3, Smad4 and Smad7 in hypertrophic scar fibroblasts.

Figure 3.

Effect of chymase on TGF-β1, P-Smad2/3, Smad4 and Smad7 protein expression in hypertrophic scar fibroblasts. (A) Western blot image displaying TGF-β1, P-Smad2/3, Smad4 and Smad7 protein levels after treatment with different concentrations of chymase (0, 60 or 120 ng/ml) for 6, 12 or 24 h. Protein expression of (B) TGF-β1, (C) P-Smad2/3, (D) Smad4 and (E) Smad7 normalized to GAPDH. All experiments were performed in triplicate. Values are expressed as the mean ± standard deviation. *P<0.05 compared with control (0 ng/ml chymase). TGF, transforming growth factor; P-SMAD2/3, phosphorylated SMAD2/3.

Discussion

Hypertrophic scars are a type of skin tissue fibrosis mediated by inflammatory cells. In the formation stage of hypertrophic scars, an increase in the mast cell number is positively correlated with the severity of fibrosis (17). Compared with normal skin, active transmitters associated with mast cells are significantly increased, suggesting that mast cells and their transmitters are key factors for promoting hypertrophic scar formation (17). Chymase secreted by mast cells participates in the formation of skin matrix (18,19). Castagnoli et al (20) demonstrated that serine proteinase secreted by mast cells facilitates the proliferation of hypertrophic scar fibroblasts by eliminating contact inhibition, and promotes collagen synthesis, secretion and deposition in extracellular matrix. Mature mast cells are only present around blood vessels, or in the skin and mucus membranes, with specific phenotypes. CD117 (c-Kit) is an important receptor on the mast cell surface that regulates its function. In the present study, immunohistochemical staining demonstrated that the number of mast cells and the level of chymase activity in hypertrophic scars are significantly higher than those in normal skin, suggesting that mast cell chymase is present and active in hypertrophic scars.

Chymase has been demonstrated to induce the proliferation of cardiac fibroblasts, and to have important roles in the development of fibrosis in the lungs and heart via angiotensin II (21,22). Angiotensin II is an important growth factor in the renin-angiotensin system. The renin-angiotensin system exists in the skin, and hypertrophic scar fibroblasts express angiotensin II receptors. The present study revealed that chymase upregulated angiotensin expression in fibroblasts isolated from hypertrophic scars. TGF-β stimulates the differentiation and proliferation of fibroblasts by regulating the synthesis and deposition of extracellular matrix. It inhibits the production of collagenase and increases the production of collagenase inhibitors, finally leading to the sustained growth of hypertrophic scars. Overexpression of TGF-β1 is a reason for the formation of hypertrophic scars (23,24). Ghahary et al (25) reported that the level of TGF-β1 mRNA in hypertrophic scars is 61% higher than that in normal skin. Tredget et al (26) demonstrated that the mRNA and protein expression of TGF-β1 in hypertrophic scars and their fibroblasts is significantly higher than that in normal skin and its cells. Similarly, the results of the present study demonstrated that mast cell chymase enhances the expression of TGF-β1 in hypertrophic fibroblasts. Type I and III collagen is the main interstitial collagen that has important roles in the structural composition of extracellular matrix (26,27). Verhaegen et al (27) demonstrated that excessive deposition of collagen promotes the formation of hypertrophic scars. The results of the present study revealed that mast cell chymase (60 and 120 ng/ml) increases the expression of type I and III collagen in hypertrophic scar fibroblasts. The present study also demonstrated that mast cell chymase enhances P-Smad2/3 as well as the protein expression of Smad4 and Smad7. The phosphorylation of Smad2/3 is a key step and marker in the Smad signaling pathway (28–30). Enhanced expression of Smad4 positively regulates the signaling pathway and activates downstream effector molecules (29,30). Smad7 is activated by TGF-β and exerts its biological effects together with TGF-β (29,30).

In conclusion, the present study demonstrated that mast cell chymase is present in hypertrophic scars with active expression. Mast cell chymase activates TGF-β1 and facilitated the synthesis of collagen in hypertrophic scar fibroblasts in vitro. In addition, chymase activated the Smads signaling pathway and enhanced Smad protein expression. Therefore, it is concluded that mast cell chymase has important roles in the formation of hypertrophic scars through the TGF-β1/Smads signaling pathway. The present study provided a basis for research into the treatment of hypertrophic scars by inhibiting the activation and release of mast cell chymase in the future.